In clinical settings, giving DSIP intravenously has been shown to reduce pain in most patients with chronic pain, including those with migraines and psychogenic pain
Common Gastrointestinal Concerns Both dual and triple agonists share a class-wide side effect profile dominated by gastrointestinal issues, primarily: Nausea Diarrhea or Constipation Vomiting These effects are dose-related and typically peak during the dose-escalation phase
In patients with early PD, the GLP-1RA lixisenatide can modestly slow the progression of motor dysfunction over 12 months of treatment, but it is associated with gastrointestinal side effects, and its long-term efficacy and safety require further verification (265)
Yes MK-677 reduces insulin sensitivity by approximately 1015% and raises fasting glucose by 510 mg/dL on average due to sustained growth hormone antagonism of insulin signaling pathways
The FDA is slowly approving more drugs to treat obesity (defined as having a BMI of 30 or greater) but the current two approved GLP-1 agents for weight loss only are Wegovy and high-dose Saxenda